Analgosedative adjuncT keTAmine Infusion iN Mechanically vENTilated ICU Patients (ATTAINMENT)
Primary Purpose
Critical Illness, Sedation, Mechanical Ventilation
Status
Completed
Phase
Phase 3
Locations
Saudi Arabia
Study Type
Interventional
Intervention
Ketamine
Sponsored by
About this trial
This is an interventional treatment trial for Critical Illness focused on measuring Ketamine, standard of care, critically ill, mechanically ventilation, ATTAINMENT, propofol, Fentanyl , midazolam , delirium, vasopressors
Eligibility Criteria
Inclusion Criteria:
- Adult ICU (Medical or surgical) patients (> 14 years old)
- Mechanically ventilated within the previous 24 hours and expected to remain intubated for more than 24 hours.
- The patient requires ongoing sedative medication
- No objection from the ICU attending MD for enrollment
Exclusion Criteria:
- Patients with a history of dementia or psychiatric disorders or on any anti-psychotics or anti-depressants medications at home
- Pregnancy
- Age < 14 years old
- Expected to need mechanical ventilation less than 24 hours
- Known hypersensitivity to ketamine
- Patient on dexmedetomidine as primary sedative agent prior to randomization
- Patients with cardiogenic shock, heart failure, myocardial infarction
- History of end-stage liver disease.
- Proven or suspected primary neurological injury (traumatic brain injury, ischemic stroke, intracranial hemorrhage, spinal cord injury, anoxic brain injury)
- Patients with persistent heart rate (HR) > 150 bpm or systolic blood pressure (SBP) >180 mmHg
- Patients who assigned as do-not-resuscitate order (DNR) or expected to die within 24 hours
- Patients on ECMO
- Patients with status epilepticus patients who are receiving the ketamine infusion for refractory status epilepticus
- Proven or suspected status asthmaticus
- Patients with expected targeted RASS of -5 such as patients on continuous infusion neuromuscular blockade
Sites / Locations
- King Faisal Specialist Hospital and Research Centre
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Ketamine Group
Control Group
Arm Description
adjunct low dose continuous infusion ketamine in addition to the standard of care. Ketamine will be given at a fixed infusion rate of 0.12 mg/kg/hr (2 µg/kg/min) in the first 24 hours followed by 0.06 mg/kg/hr (1 µg/kg/min) in the second 24 hours, then discontinued
Standard of care in the ICU including propofol and / or fentanyl and/or midazolam according to KFSHRC sedation and analgesia protocol.
Outcomes
Primary Outcome Measures
Duration of Mechanical Ventilation
To assess whether ketamine can help to shorten the time of being in breathing tube and ventilator (duration of mechanical ventilation )
Secondary Outcome Measures
Cumulative Sedation Dosages
To compare the cumulative dose of pain and sedative medications.
Dexmedetomidine use
To compare the number of patients started on dexmedetomidine.
Richmond Agitation Sedation Score (RASS)
To compare The number of patients are in RASS score goal.
Pain score
To compare The number of patients are in pain score goal. We will use the KFSHRC pain scale being used in our ICU.
For Adult communicative patients, we will use a scale from 0-10. The "0" indicates "No pain" and "10" indicates "severe pain". Values between 1-3 indicate mild pain, values between 4-6 indicate moderate pain while values between 7-10 indicate severe pain.
For non-communicative patients, A scale is composed of five categories: Physiology, Facial expressions, Activity (movement), Guarding And Respiratory, will be used. Each Category has a scale 0-2, then the total score is calculated and should be between 0-10. Values between 0-2 indicate no pain, values 3-6 indicate moderate pain while values between 7-10 indicate severe pain.
Vasopressor Medication Dosages
To compare vasopressor requirement.
Hemodynamics
Changes in Mean Arterial Blood Pressure (MAP) and Heart Rate (HR)
Frequency of endotracheal tube Suctioning
Proportion of patient with changes in requirements of suctioning frequency to 2 hours of less
Hospital Length of Stay (LOS)
To compare hospital LOS
ICU Length of stay (LOS)
To compare ICU LOS
Tracheostomy
Tracheostomy rate
Unplanned extubation
Rate of unplanned extubation
Re-intubation rate
Rate of unplanned and unexpected re-intubation
Full Information
NCT ID
NCT04075006
First Posted
August 28, 2019
Last Updated
May 5, 2021
Sponsor
King Faisal Specialist Hospital & Research Center
1. Study Identification
Unique Protocol Identification Number
NCT04075006
Brief Title
Analgosedative adjuncT keTAmine Infusion iN Mechanically vENTilated ICU Patients
Acronym
ATTAINMENT
Official Title
Adjunct Low Dose Ketamine Infusion Versus Standard of Care in Mechanically Ventilated Critically Ill Patients at a Tertiary Saudi Hospital: Randomized, Prospective, Pilot Trial
Study Type
Interventional
2. Study Status
Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
August 28, 2019 (Actual)
Primary Completion Date
May 6, 2021 (Actual)
Study Completion Date
May 6, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
King Faisal Specialist Hospital & Research Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
5. Study Description
Brief Summary
The purpose of this study is to investigate the efficacy and safety of a low dose ketamine infusion used in combination of standard of care in critically ill patients to test whether ketamine can help to shorten the time of being in breathing tube and ventilator compared to the standard of care alone.
Detailed Description
Ketamine is used to produce sedation and relieve pain to minimize discomfort while a breathing tube placed in trachea (windpipe) and a machine (ventilator) used in the ICU. Several publications have shown that a low-dose ketamine in combination to opioids has been used to relieve acute pain after surgery. Ketamine has a favorable characteristics including bronchodilation, increase in blood pressure, does not cause constipation , maintain respiratory reflexes (respiratory spontaneous responses) make it an especially viable alternative for patients with unstable respiratory and hemodynamic function. However, the majority of these trials are conducted in a surgical ICU setting, retrospective in nature or randomized controlled clinical trials focusing on comparison of ketamine to placebo or two study drugs (e.g. ketamine versus opioid), despite the fact that most ICU patients are sedated with a combination of drugs. Moreover, the majority of those trials has a limited focus on patient-centered outcomes, as the primary outcome.
The aim of this study is to assess weather ketamine can help to shorten the time of being in breathing tube and ventilator (duration of mechanical ventilation). This is a prospective, randomized, active controlled, open-label pilot study to assess the efficacy and safety of Analgo-sedative adjuncT keTAmine Infusion iN Mechanically vENTilated ICU patients (ATTAINMENT trial). The study hypothesis is that low dose ketamine infusion will reduce the duration of mechanical ventilation with an acceptable safety profile compared to standard of care. The study will include adult ICU patients (> 14 years old) admitted to KFSHRC ICUs within the previous 24 hours, placed on the ventilator, expected to need breathing tube for longer than 24 hours and placed on KFSHRC sedation and pain protocol. Patients will be separated to 2 groups: The intervention group: will receive a low dose ketamine infusion used in combination of standard of care. Ketamine will be given as intravenous infusion at a fixed infusion rate 0.12 mg/kg/hr (2 µg/kg/min) in 1st 24hr followed by 0.06 mg/kg/hr (1 µg/kg/min) in 2nd 24hr. The control group which will receive standard of care in the ICU including propofol and / or fentanyl and/or midazolam according to KFSHRC ICU sedation and analgesia protocol as chosen by the treating clinician.The randomization process is computer-generated using block randomization with a size of 8 patients in each block.
The number of the subjects to be enrolled in this study is 80 and duration of the subject's participation is 48hrs. Patients will be assessed for duration of mechanical ventilation as a primary outcome.
Study medication (i.e. ketamine) will be administered until one the following occurs:
Patient has received ketamine for 48 hours (intended duration if the study), or
If ICU team deemed excessive sedation persisted after holding or decreasing the sedating medication and patient not on target sedation score called RASS,
Patient died or goal of care changed to comfort care
Patient extubated and sedation weaned off ,
an adverse event potentially attributable to the study drug is experienced by a patient that is deemed, in the opinion of the investigative team to warrant discontinuation of therapy such as fast heart beat persist >150 beat per min for more than 3 hours, high systolic blood pressure persist > 180 for more than 3 hours, severe agitation and pulling off breathing tube or lines, and aggressive behavior to the nursing staff.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Critical Illness, Sedation, Mechanical Ventilation
Keywords
Ketamine, standard of care, critically ill, mechanically ventilation, ATTAINMENT, propofol, Fentanyl , midazolam , delirium, vasopressors
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
84 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Ketamine Group
Arm Type
Experimental
Arm Description
adjunct low dose continuous infusion ketamine in addition to the standard of care. Ketamine will be given at a fixed infusion rate of 0.12 mg/kg/hr (2 µg/kg/min) in the first 24 hours followed by 0.06 mg/kg/hr (1 µg/kg/min) in the second 24 hours, then discontinued
Arm Title
Control Group
Arm Type
No Intervention
Arm Description
Standard of care in the ICU including propofol and / or fentanyl and/or midazolam according to KFSHRC sedation and analgesia protocol.
Intervention Type
Drug
Intervention Name(s)
Ketamine
Intervention Description
standard of care plus Ketamine infusion at a fixed rate of 0.12 mg/kg/hr (2 µg/kg/min) in the first 24 hours followed by 0.06 mg/kg/hr (1 µg/kg/min) in the second 24 hours, then discontinued
Primary Outcome Measure Information:
Title
Duration of Mechanical Ventilation
Description
To assess whether ketamine can help to shorten the time of being in breathing tube and ventilator (duration of mechanical ventilation )
Time Frame
From Intubation to extubation date and off Mechanical Ventilation or until ICU discharge, death, or 28 days post randomization whichever occurs first.
Secondary Outcome Measure Information:
Title
Cumulative Sedation Dosages
Description
To compare the cumulative dose of pain and sedative medications.
Time Frame
First 48 hours after randomization
Title
Dexmedetomidine use
Description
To compare the number of patients started on dexmedetomidine.
Time Frame
First 48 hours after randomization
Title
Richmond Agitation Sedation Score (RASS)
Description
To compare The number of patients are in RASS score goal.
Time Frame
First 48 hours after randomization
Title
Pain score
Description
To compare The number of patients are in pain score goal. We will use the KFSHRC pain scale being used in our ICU.
For Adult communicative patients, we will use a scale from 0-10. The "0" indicates "No pain" and "10" indicates "severe pain". Values between 1-3 indicate mild pain, values between 4-6 indicate moderate pain while values between 7-10 indicate severe pain.
For non-communicative patients, A scale is composed of five categories: Physiology, Facial expressions, Activity (movement), Guarding And Respiratory, will be used. Each Category has a scale 0-2, then the total score is calculated and should be between 0-10. Values between 0-2 indicate no pain, values 3-6 indicate moderate pain while values between 7-10 indicate severe pain.
Time Frame
First 48 hours after randomization
Title
Vasopressor Medication Dosages
Description
To compare vasopressor requirement.
Time Frame
First 48 hours after randomization.
Title
Hemodynamics
Description
Changes in Mean Arterial Blood Pressure (MAP) and Heart Rate (HR)
Time Frame
First 48 hours after randomization
Title
Frequency of endotracheal tube Suctioning
Description
Proportion of patient with changes in requirements of suctioning frequency to 2 hours of less
Time Frame
First 48 hours after randomization
Title
Hospital Length of Stay (LOS)
Description
To compare hospital LOS
Time Frame
Throughout study completion (1 year)
Title
ICU Length of stay (LOS)
Description
To compare ICU LOS
Time Frame
Throughout study completion (1 year)
Title
Tracheostomy
Description
Tracheostomy rate
Time Frame
28 days after randomization
Title
Unplanned extubation
Description
Rate of unplanned extubation
Time Frame
28 days after randomization
Title
Re-intubation rate
Description
Rate of unplanned and unexpected re-intubation
Time Frame
28 days after randomization
Other Pre-specified Outcome Measures:
Title
Incidence of Delirium
Description
Rate of positive Confusion Assessment Method in Intensive Care Unit (CAM-ICU)
Time Frame
48 hours after randomization
Title
The use of anti-psychotics
Description
Rate of using anti-psychotics for confirmed ICU-acquired delirium
Time Frame
48 hours after randomization
Title
Use of Physical restraints
Description
Use of physical restraints
Time Frame
48 hours after randomization
Title
Mortality
Description
Death that occurs during 28 days
Time Frame
28 days after randomization
10. Eligibility
Sex
All
Minimum Age & Unit of Time
14 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult ICU (Medical or surgical) patients (> 14 years old)
Mechanically ventilated within the previous 24 hours and expected to remain intubated for more than 24 hours.
The patient requires ongoing sedative medication
No objection from the ICU attending MD for enrollment
Exclusion Criteria:
Patients with a history of dementia or psychiatric disorders or on any anti-psychotics or anti-depressants medications at home
Pregnancy
Age < 14 years old
Expected to need mechanical ventilation less than 24 hours
Known hypersensitivity to ketamine
Patient on dexmedetomidine as primary sedative agent prior to randomization
Patients with cardiogenic shock, heart failure, myocardial infarction
History of end-stage liver disease.
Proven or suspected primary neurological injury (traumatic brain injury, ischemic stroke, intracranial hemorrhage, spinal cord injury, anoxic brain injury)
Patients with persistent heart rate (HR) > 150 bpm or systolic blood pressure (SBP) >180 mmHg
Patients who assigned as do-not-resuscitate order (DNR) or expected to die within 24 hours
Patients on ECMO
Patients with status epilepticus patients who are receiving the ketamine infusion for refractory status epilepticus
Proven or suspected status asthmaticus
Patients with expected targeted RASS of -5 such as patients on continuous infusion neuromuscular blockade
Facility Information:
Facility Name
King Faisal Specialist Hospital and Research Centre
City
Riyadh
ZIP/Postal Code
11211
Country
Saudi Arabia
12. IPD Sharing Statement
Citations:
PubMed Identifier
34462007
Citation
Amer M, Maghrabi K, Bawazeer M, Alshaikh K, Shaban M, Rizwan M, Amin R, De Vol E, Baali M, Altewerki M, Bano M, Alkhaldi F, Alenazi S, Hijazi M. Adjunctive ketamine for sedation in critically ill mechanically ventilated patients: an active-controlled, pilot, feasibility clinical trial. J Intensive Care. 2021 Aug 30;9(1):54. doi: 10.1186/s40560-021-00569-1.
Results Reference
derived
PubMed Identifier
32197636
Citation
Bawazeer M, Amer M, Maghrabi K, Alshaikh K, Amin R, Rizwan M, Shaban M, De Vol E, Hijazi M. Adjunct low-dose ketamine infusion vs standard of care in mechanically ventilated critically ill patients at a Tertiary Saudi Hospital (ATTAINMENT Trial): study protocol for a randomized, prospective, pilot, feasibility trial. Trials. 2020 Mar 20;21(1):288. doi: 10.1186/s13063-020-4216-4.
Results Reference
derived
Learn more about this trial
Analgosedative adjuncT keTAmine Infusion iN Mechanically vENTilated ICU Patients
We'll reach out to this number within 24 hrs